Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of
EGFR
,
ALK
,
ROS1
,
KRAS
or
BRAF
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):